Marc van Beurden
Overview
Explore the profile of Marc van Beurden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Terra L, Heemskerk-Gerritsen B, Beekman M, Engelhardt E, Mourits M, van Doorn H, et al.
BJOG
. 2023 Jul;
131(1):99-108.
PMID: 37394722
Objective: To study the impact of premenopausal risk-reducing salpingo-oophorectomy (RRSO), compared with postmenopausal RRSO, on urinary incontinence (UI) ≥10 years later. Design: Cross-sectional study, nested in a nationwide cohort. Setting:...
12.
Voss F, Thuijs N, Duin S, Ozer M, van Beurden M, Berkhof J, et al.
Int J Cancer
. 2023 Apr;
153(4):783-791.
PMID: 37074263
The precursor lesions of vulvar squamous cell carcinoma (VSCC) include human papillomavirus (HPV)-associated and HPV-independent squamous neoplasia with a varying cancer risk. Our study aimed to validate the accuracy of...
13.
Terra L, Lee Meeuw Kjoe P, Agelink van Rentergem J, Beekman M, Heemskerk-Gerritsen B, van Beurden M, et al.
BJOG
. 2023 Jan;
130(8):968-977.
PMID: 36715559
Objective: To examine the effect of a premenopausal risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of ovarian cancer on objective and subjective cognition at least 10 years after RRSO....
14.
Terra L, Beekman M, Engelhardt E, Heemskerk-Gerritsen B, van Beurden M, Roeters van Lennep J, et al.
Am J Obstet Gynecol
. 2022 Nov;
228(4):440.e1-440.e20.
PMID: 36403862
Background: Women with a BRCA1/2 pathogenic variant are advised to undergo premenopausal risk-reducing salpingo-oophorectomy after completion of childbearing, to reduce their risk of ovarian cancer. Several studies reported less sexual...
15.
Preti M, Joura E, Vieira-Baptista P, van Beurden M, Bevilacqua F, Bleeker M, et al.
J Low Genit Tract Dis
. 2022 Jun;
26(3):229-244.
PMID: 35763611
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European...
16.
Preti M, Joura E, Vieira-Baptista P, van Beurden M, Bevilacqua F, Bleeker M, et al.
Int J Gynecol Cancer
. 2022 Jun;
32(7):830-845.
PMID: 35728950
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European...
17.
van Winden L, Vermeulen R, van den Noort V, Gaarenstroom K, Kenter G, Brood-van Zanten M, et al.
J Endocr Soc
. 2022 May;
6(6):bvac069.
PMID: 35592509
Context: Risk-reducing salpingo-oophorectomy (RRSO) is performed in BRCA1 or 2 mutant carriers to minimize ovarian cancer risk. Although studies have been performed investigating sex steroid levels, menopausal complaints, and sexual...
18.
Voss F, van Beurden M, Jordanova E
Lancet
. 2022 Apr;
399(10337):1755-1757.
PMID: 35483402
No abstract available.
19.
van der Linden M, van Hees C, van Beurden M, Bulten J, van Dorst E, Esajas M, et al.
Am J Obstet Gynecol
. 2022 Apr;
227(2):250.e1-250.e8.
PMID: 35447145
Background: Vulvar Paget disease is an extremely rare skin disorder, which is most common in postmenopausal women. Most vulvar Paget disease cases are noninvasive; however, it may be invasive or...
20.
Van Bommel M, Steenbeek M, IntHout J, Hermens R, Hoogerbrugge N, Harmsen M, et al.
Support Care Cancer
. 2022 Jan;
30(4):3409-3418.
PMID: 34997316
Objective: High cancer risks, as applicable to BRCA1 and BRCA2 pathogenic variant (PV) carriers, can induce significant cancer concerns. We examined the degree of cancer worry and the course of...